0.27%
11.03%
68.93%
97.18%
303.81%
109.81%
33.69%

Company Description

ChromaDex Corporation operates as a bioscience company focusing on healthy aging.The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services.It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.


The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function.It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries.The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States.


ChromaDex Corporation is headquartered in Los Angeles, California.

Market Data

Last Price 5.9
Change Percentage 0.27%
Open 5.88
Previous Close 5.88
Market Cap ( Millions) 450
Volume 6106
Year High 7.97
Year Low 1.46
M A 50 6.27
M A 200 4.14

Financial Ratios

FCF Yield 0.88%
Dividend Yield 0.00%
ROE 4.85%
Debt / Equity 8.42%
Net Debt / EBIDTA -1516.08%
Price To Book 13.03
Price Earnings Ratio 301.62
Price To FCF 113.32
Price To sales 4.46
EV / EBITDA 216.25

News

Business Breakdown

Expected Mid-Term Growth

Segment n°1 -> Consumer Products

Expected Growth : 15 %

What the company do ?

ChromaDex Corporation's Consumer Products segment offers a range of healthy aging and wellness products, including Tru Niagen, a patented nicotinamide riboside (NR) supplement.

Why we expect these perspectives ?

ChromaDex Corporation's 15% growth in Consumer Products is driven by increasing demand for healthy aging and wellness products, particularly among the aging population. The company's proprietary Nicotinamide Riboside (NR) ingredient, a key component in its Tru Niagen supplement, is a major contributor to this growth. Additionally, expanding distribution channels, strategic partnerships, and a growing e-commerce presence also support the segment's rapid growth.

Segment n°2 -> Ingredients

Expected Growth : 12 %

What the company do ?

ChromaDex's Ingredients are proprietary, scientifically-backed, and patented ingredients, including Niagen, TRU NIAGEN, and others, designed to support healthy aging and wellness.

Why we expect these perspectives ?

ChromaDex Corporation's 12% growth is driven by increasing demand for healthy aging and wellness products, rising adoption of Tru Niagen, a proprietary nicotinamide riboside (NR) ingredient, and expansion into new markets. Additionally, growing awareness of the importance of nicotinamide adenine dinucleotide (NAD+) in energy metabolism and DNA repair is fueling demand for ChromaDex's ingredients.

Segment n°3 -> Analytical Reference Standards and Services

Expected Growth : 10 %

What the company do ?

Analytical Reference Standards and Services from ChromaDex Corporation provide authenticated and certified reference materials for quality control and analytical testing in the pharmaceutical, nutraceutical, and food industries.

Why we expect these perspectives ?

ChromaDex's Analytical Reference Standards and Services segment growth is driven by increasing demand for quality control in the pharmaceutical, nutraceutical, and food industries. Rising regulatory requirements, growing consumer awareness of product safety, and the need for precise analytical testing are key factors contributing to 10% growth.

Chromadex Corporation Products

Product Range What is it ?
TRU NIAGEN A proprietary nicotinamide riboside (NR) supplement that supports energy metabolism and overall health
Immulina A proprietary, patented, and clinically-tested beta-1,3-D glucan ingredient that supports immune system function
pTeroPure A proprietary, patented, and clinically-tested pterostilbene antioxidant supplement that supports heart health and cognitive function
Nicotinamide Riboside (NR) A vitamin B3 derivative that supports energy metabolism, mitochondrial function, and overall health
ChromaDex External Sales A range of proprietary, patented, and clinically-tested ingredients sold to third-party companies for use in their products

ChromaDex Corporation's Porter Forces

ChromaDex Corporation's products are highly specialized and unique, making it difficult for substitutes to emerge.

While ChromaDex Corporation has a diverse customer base, some large customers may have bargaining power due to their significant purchasing volumes.

ChromaDex Corporation has a diversified supplier base, reducing the bargaining power of individual suppliers.

The nutritional supplement industry is highly competitive, and new entrants may emerge, posing a threat to ChromaDex Corporation's market share.

The nutritional supplement industry is highly competitive, with many established players, leading to a high intensity of rivalry.

Capital Structure

Value
Debt Weight 10.33%
Debt Cost 3.95%
Equity Weight 89.67%
Equity Cost 13.76%
WACC 12.74%
Leverage 11.52%

Historical Valuation

Price/Earnings Ratio

Margin Valuation

Peers Valuation

Competitors

Company Rational
LGND Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which …
YMAB Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers …
PTGX Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable …
ARDX Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, …
BYSI BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent …

Peers Metrics

DCF BETA

Parameters

Short Term Growth
Short term Time
Long-Term Growth
WACC
Target Price
5.9$
Current Price
5.9$
Potential
-0.00%

Expected Cash-Flows

Scoring Insights

Peers Group Analysis

🥇

Ligand Pharmaceuticals Logo
Ligand Pharmaceuticals
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

🥈

Protagonist Therapeutics Logo
Protagonist Therapeutics
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

🥉

BeyondSpring Logo
BeyondSpring
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

4

Y-mAbs Therapeutics Logo
Y-mAbs Therapeutics
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

5

ChromaDex Logo
ChromaDex
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

6

Ardelyx Logo
Ardelyx
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->